Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-25T00:56:58.748Z Has data issue: false hasContentIssue false
  • English
  • Français

Severe hypertriglyceridemia associated with everolimus drug-eluting stent placement in an infant

Part of: Interventional Cardiology

Published online by Cambridge University Press:  08 April 2019

Kuan-Chi Lai Open the ORCID record for Kuan-Chi Lai [Opens in a new window] ,
Julie A. Brothers  and
Jason Z. Stoller
Kuan-Chi Lai
Affiliation:
Division of Neonatology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Julie A. Brothers
Affiliation:
Division of Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Jason Z. Stoller*
Affiliation:
Division of Neonatology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
*
Author for correspondence: Jason Z. Stoller, Children’s Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA 19104, USA. Tel: 215-590-1653; Fax: 215-590-3051; E-mail: stoller@email.chop.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

We report a case of severe hypertriglyceridemia associated with an everolimus drug-eluting stent in an infant with pulmonary vein stenosis. We review from current literature the mechanisms by which everolimus may cause dyslipidaemia, pharmacokinetics of everolimus in drug-eluting stents, and treatments of hypertriglyceridemia. This case demonstrates the need to closely monitor serum triglyceride levels after everolimus drug-eluting stent placement in infants.

Keywords

Catheterisationdrug-eluting stentpaediatricsdyslipidaemia
Type
Brief Report
Information
Cardiology in the Young , Volume 29 , Issue 4 , April 2019 , pp. 541 - 543
Copyright
© Cambridge University Press 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Vergès, B, Walter, T, Cariou, B. Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 2014; 170: R43–55.CrossRefGoogle ScholarPubMed
Stefanini, GG, Holmes, DR. Drug-eluting coronary-artery stents. N Engl J Med. 2013; 368: 254–265.CrossRefGoogle ScholarPubMed
Fink, T, Schlüter, M, Heeger, C-H, et al. Pulmonary vein stenosis or occlusion after catheter ablation of atrial fibrillation: long-term comparison of drug-eluting versus large bare metal stents. EP Europace 2018; 20: e148–e155.CrossRefGoogle ScholarPubMed
Cory, MJ, Ooi, YK, Kelleman, MS, Vincent, RN, Kim, DW, Petit, CJ. Reintervention is associated with improved survival in pediatric patients with pulmonary vein stenosis. JACC Cardiovasc Interv 2017; 10: 1788–1798.CrossRefGoogle ScholarPubMed
Balasubramanian, S, Marshall, AC, Gauvreau, K, et al. Outcomes after stent implantation for the treatment of congenital and postoperative pulmonary vein stenosis in children. Circ Cardiovasc Interv 2012; 5: 109–117.CrossRefGoogle ScholarPubMed
Subramaniam, S, Zell, JA, Kunz, PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. J Natl Compr Cancer Netw 2013; 11: 5–9.CrossRefGoogle ScholarPubMed
Wiemer, M, Seth, A, Chandra, P, et al. Systemic exposure of everolimus after stent implantation: a pharmacokinetic study. Am Heart J 2008; 156: 751.e1–757.CrossRefGoogle ScholarPubMed
Müller, MJ, Krause, U, Paul, T, Schneider, HE. Serum levels after everolimus-stent implantation and paclitaxel-balloon angioplasty in an infant with recurrent pulmonary vein obstruction after repaired total anomalous pulmonary venous connection. Pediatr Cardiol 2011; 32: 1036–1039.CrossRefGoogle Scholar
Fairchild, KD, Patterson, A, Gumpper, KF. Overdose of intravenous fat emulsion in a preterm infant: case report. Nutr Clin Pract 1999; 14: 116–119.CrossRefGoogle Scholar